The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Sarah Silbiger/Getty Images
By Adam Feuerstein
May 7, 2026
Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.
Adam Feuerstein
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Investors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S.…
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match them…
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
